RecruitingPhase 3NCT06752356

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Studying Chronic inflammatory demyelinating polyneuropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kedrion S.p.A.
Principal Investigator
Miranda Norton, PhD
Kedrion S.p.A.
Intervention
Immune globulin (human) 10% solution for intravenous administration(biological)
Enrollment
161 enrolled
Eligibility
18 years · All sexes
Timeline
20262027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06752356 on ClinicalTrials.gov

Other trials for Chronic inflammatory demyelinating polyneuropathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic inflammatory demyelinating polyneuropathy

← Back to all trials